Rasio rega marang prakiraan pendapatan Biomerica (BMRA)

Biomerica Inc (BMRA) - logo korporat

Biomerica, Inc. (BMRA) leverages its patented food intolerance analysis methods to maintain significant pricing power. The projected market cap-to-revenue ratio confirms this status, with the parameter reaching 1.40. The company is scaling the implementation of InFoods systems to combat IBS, thereby expanding its market influence, although gastroenterologist loyalty is constrained by strict FDA oversight of at-home diagnostics.

BMRA biomerica.com: Multiplikator forward rega marang pendapatan ing interval 04.07.2022 - 16.11.2026

Rincian metrik komprehensif lan analitis Biomerica, Inc. (BMRA)

- rega saiki lan proyeksi nilai saham:
Analisis komprehensif perusahaan:Biomerica Inc BMRA
Produk asli Biomerica Inc

Biomerica, Inc. (BMRA) strategic alliances in rapid diagnostics and personalized nutrition directly determine the scale of future cash flows. The company's future P/S dynamics reflect the ratio of market value to expected revenue, serving as an indicator of a fundamental pivot and the speed of commercial recovery, which allows investors to assess the business's margin of safety and the risk of inflated expectations ahead of a potential correction.

Pesaing Biomerica, Inc. (BMRA)

Multiplikator Forward P/S A (agilent.com)|Quest Corp (DGX) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|ILMN - Rasio rega marang prakiraan pendapatan|EXAS - Multiplikator Forward P/S|RVTY (Revvity) - Multiplikator forward rega marang pendapatan|Bio-Rad - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan anbio.com|Multiplikator Forward P/S Sotera Health Company|Rasio rega marang prakiraan pendapatan QuidelOrtho (QDEL)|OPK - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|caredx.com - Multiplikator forward rega marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Maravai LifeSciences Corp (MRVI)|FLGT: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan LAB (Fluidigm)|Cytek Biosciences Inc (CTKB) - Rasio rega marang prakiraan pendapatan|OSUR: Rasio rega marang pendapatan sing dikarepake|Multiplikator forward rega marang pendapatan XGN|MDXH: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Lucid Diagnostics Inc. (LUCD)|Rasio rega marang prakiraan pendapatan PRE (Prenetics Global Limited)|Multiplikator Forward P/S IMDX (Insight Molecular Diagnostics Inc)|Rasio rega marang pendapatan sing dikarepake TRIB (Trinity Biotech Corp)|PRPH - Rasio rega marang prakiraan pendapatan|Ainos (AIMD) - Multiplikator forward rega marang pendapatan|CoDx (CODX) - Rasio rega marang prakiraan pendapatan|HSCS (Heart Test Labs) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan CDIO|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep onconetix.gcs-web.com ONCO|Rasio rega marang prakiraan pendapatan Virax Biolabs (VRAX)|Rasio rega marang pendapatan sing dikarepake BJDX|Rasio rega marang prakiraan pendapatan Vermillion AWH|Accelerate Diagnostics Inc (AXDX) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|centogene.com - Multiplikator Forward P/S|ENZ (Enzo Biochem Inc.) - Kapitalisasi marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep FRES|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep GTG Labs (GENE)|ME (23andme.com) - Multiplikator Forward P/S|Multiplikator Forward P/S Psychemedics Inc